Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

NCT05545072 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped The study was terminated due to funding ending.

Conditions

Allergic Fungal Rhinosinusitis

Interventions

DRUG: Dupilumab
DRUG: Placebo
DRUG: Intranasal Corticosteroid Sprays (INCS)

Sponsor

Emory University

Collaborators

[object Object]